MRTX - Mirati Therapeutics, Inc.

NasdaqGS - NasdaqGS Prezzo in tempo reale. Valuta in USD.

Mirati Therapeutics, Inc.

3545 Cray Court
San Diego, CA 92121
United States
858 332 3410

Impiegati a tempo pieno587

Figure dirigenziali chiave

NomeTitoloRetribuzioneEsercitateAnno di nascita
Mr. David D. MeekCEO & Director1,66MN/D1963
Dr. Charles M. Baum M.D., Ph.D.Founder, Pres, Head of R&D and Director1,07M6,05M1958
Ms. Laurie D. StelzerChief Financial Officer609,06kN/D1968
Dr. James G. Christensen Ph.D.Exec. VP & Chief Scientific Officer1,76MN/D1968
Dr. Alan Bart Sandler M.D.Exec. VP & Chief Medical Officer591kN/D1957
Mr. John B. Moriarty Jr., J.D.Chief Legal OfficerN/DN/D1968
Mr. Michael E. PaolucciChief People OfficerN/DN/D1960
Mr. Benjamin J. Hickey M.B.A.Chief Commercial OfficerN/DN/D1975
Dr. Kelly Covello Ph.D.VP & Head of Medical AffairsN/DN/DN/D
Mr. Ryan AsayVP & Head of Corp. AffairsN/DN/DN/D
Gli importi risalgono al giorno 31 dicembre 2022 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.


Mirati Therapeutics, Inc., a commercial-stage oncology company, develops novel therapeutics to address the genetic and immunological promoters of cancer in the United States. The company provides KRAZATI, an oral targeted treatment option for adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung (NSCLC), as well as in clinical development as a monotherapy and in combination with other agents. It also develops Sitravatinib, an investigational spectrum-selective kinase inhibitor in Phase 3 clinical development that inhibits receptor tyrosine kinases (RTKs), including TAM family receptors, split family receptors, and RET, which overcomes resistance to checkpoint inhibitor therapy through targeted reversal of an immunosuppressive tumor microenvironment that enhances antigen-specific T cell response and expanding dendritic cell-dependent antigen presentation. In addition, the company pipeline comprises the MRTX1719, an investigational synthetic lethal PRMT5 inhibitor designed to target the PRMT5/methylthioadensoine (MTA) complex and is in clinical development; MRTX0902, a selective SOS1 inhibitor that improves anti-tumor efficacy in combination with targeted mitogen-activated protein kinase (MAPK)-pathway inhibitors, and is in clinical development; and MRTX1133, an investigational lead KRAS G12D compound. It has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib; and Zai Lab Ltd. to research, develop, manufacture, and commercialize adagrasib in various indications. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.

Governance aziendale

L'ISS Governance QualityScore di Mirati Therapeutics, Inc. al 1 maggio 2023 è 3. I criteri di valutazione fondamentali sono revisione: 4; Consiglio di Amministrazione: 2; diritti degli azionisti: 3; retribuzione: 6.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.